Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer

被引:37
|
作者
Lei, Xueping [1 ,2 ,3 ]
Zhong, Yihang [1 ,2 ,3 ]
Huang, Lijuan [1 ,2 ,3 ]
Li, Songpei [1 ,2 ,3 ]
Fu, Jijun [1 ,2 ,3 ]
Zhang, Lingmin [1 ,2 ,3 ]
Zhang, Yu [1 ,2 ,3 ]
Deng, Qiudi [4 ,5 ]
Yu, Xiyong [1 ,2 ,3 ]
机构
[1] Guangzhou Med Univ, Key Lab Mol Target & Clin Pharmacol, Guangzhou 511436, Guangdong, Peoples R China
[2] Guangzhou Med Univ, State Key Lab Resp Dis, Sch Pharmaceut Sci, Guangzhou 511436, Guangdong, Peoples R China
[3] Guangzhou Med Univ, Affiliated Hosp 5, Guangzhou 511436, Guangdong, Peoples R China
[4] Guangzhou Med Univ, GMU GIBH Joint Sch Life Sci, Guangzhou 511436, Peoples R China
[5] Guangzhou Med Univ, Affiliated Hosp 3, Guangzhou 511436, Peoples R China
基金
中国国家自然科学基金;
关键词
SONIC HEDGEHOG; PRISTIMERIN; ACTIVATION; MECHANISMS;
D O I
10.1038/s41419-020-2425-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Although angiogenesis inhibitors targeting VEGF/VEGFR2 have been applied for tumor therapy, the outcomes are still unsatisfactory. Thus, it is urgent to develop novel angiogenesis inhibitor for cancer therapy from new perspectives. Identification of novel angiogenesis inhibitor from natural products is believed to be one of most promising strategy. In this study, we showed that pristimerin, an active agent isolated from traditional Chinese herbal medicine Celastrus aculeatus Merr, was a novel tumor angiogenesis inhibitor that targeting sonic hedgehog (Shh)/glioma associated oncogene 1 (Gli1) signaling pathway in non-small cell lung cancer (NSCLC). We showed that pristimerin affected both the early- and late-stage of angiogenesis, suggesting by that pristimerin inhibited Shh-induced endothelial cells proliferation, migration, invasion as well as pericytes recruitment to the endothelial tubes, which is critical for the new blood vessel maturation. It also suppressed tube formation, vessel sprouts formation and neovascularization in chicken embryo chorioallantoic membrane (CAM). Moreover, it significantly decreased microvessel density (MVD) and pericyte coverage in NCI-H1299 xenografts, resulting in tumor growth inhibition. Further research revealed that pristimerin suppressed tumor angiogenesis by inhibiting the nucleus distribution of Gli1, leading to inactivation of Shh/Gli1 and its downstream signaling pathway. Taken together, our study showed that pristimerin was a promising novel anti-angiogenic agent for the NSCLC therapy and targeting Shh/Gli1 signaling pathway was an effective approach to suppress tumor angiogenesis.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer
    Xueping Lei
    Yihang Zhong
    Lijuan Huang
    Songpei Li
    Jijun Fu
    Lingmin Zhang
    Yu Zhang
    Qiudi Deng
    Xiyong Yu
    Cell Death & Disease, 11
  • [2] Endoglin targeting inhibits tumor angiogenesis in non-small cell lung cancer
    Chen, Chiao-Yun
    Sheu, Ming-Jyh
    FASEB JOURNAL, 2018, 32 (01):
  • [3] Tumor angiogenesis of non-small cell lung cancer
    Shijubo, N
    Kojima, H
    Nagata, M
    Ohchi, T
    Suzuki, A
    Abe, S
    Sato, N
    MICROSCOPY RESEARCH AND TECHNIQUE, 2003, 60 (02) : 186 - 198
  • [4] Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer
    Bilal Piperdi
    Amartej Merla
    Roman Perez-Soler
    Drugs, 2014, 74 : 403 - 413
  • [5] Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer
    Lammers, Philip E.
    Horn, Leora
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (10): : 1235 - 1247
  • [6] Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer
    Piperdi, Bilal
    Merla, Amartej
    Perez-Soler, Roman
    DRUGS, 2014, 74 (04) : 403 - 413
  • [7] GLI1 activation is a key mechanism of erlotinib resistance in human non-small cell lung cancer
    Dong, Zhouhuan
    Wang, Yun
    Ding, Vivianne
    Yan, Xiang
    Lv, Yali
    Zhong, Mei
    Zhu, Fengwei
    Zhao, Po
    He, Charlotte
    Ding, Feng
    Shi, Huaiyin
    ONCOLOGY LETTERS, 2020, 20 (04)
  • [8] CONNECTING GLI1 WITH CHEMORESISTANCE IN SMALL CELL LUNG CANCER
    Weiss, Glen J.
    Allen, Kristi E.
    Edwards, David K.
    Cherni, Irene
    Lorenzo, Carlos
    Arora, Shilpi
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S701 - S701
  • [9] Connecting Gli1 with chemoresistance in small cell lung cancer
    Allen, Kristi E.
    Arora, Shilpi
    Lorenzo, Carlos
    Weiss, Glen J.
    CANCER RESEARCH, 2011, 71
  • [10] Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
    Tomasini, Pascale
    Walia, Preet
    Labbe, Catherine
    Jao, Kevin
    Leighl, Natasha B.
    ONCOLOGIST, 2016, 21 (12): : 1450 - 1460